Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 10, 2019 08:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Recaps ELZONRIS Clinical Data Presentations in Patients with Myelofibrosis (oral presentation) and Multiple Myeloma at the 61st American Society of Hematology (ASH) Annual Meeting

NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
December 06, 2019 18:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Names Robert M. Francomano Chief Commercial Officer

NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
December 06, 2019 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Highlights Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting

NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
November 29, 2019 13:05 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at Piper Jaffray’s 31st Annual Healthcare Conference

NEW YORK, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
November 07, 2019 16:57 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Reports Third Quarter 2019 Financial Results

Net revenue for ELZONRIS® was $13.3 million for the third quarterNew patient starts estimated to have increased greater than 20% from last quarterConference call and live webcast scheduled for...
November 06, 2019 09:15 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting

NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
November 05, 2019 16:22 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Host Conference Call on Third Quarter 2019 Financial Results on November 8, 2019

NEW YORK, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
October 08, 2019 07:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces ELZONRIS® Clinical Data Selected for Oral Presentation at the 81st Annual Meeting of the Japanese Society of Hematology

NEW YORK, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
October 01, 2019 07:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Recaps Felezonexor (SL-801) Clinical Data Presentation From ESMO 2019 Congress

NEW YORK, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
September 27, 2019 07:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Felezonexor (SL-801) Clinical Data to be Featured at Upcoming ESMO 2019 Congress

NEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right